Enanta Pharmaceuticals (ENTA) Operating Income (2016 - 2025)
Historic Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.3 million.
- Enanta Pharmaceuticals' Operating Income rose 5220.24% to -$11.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$73.1 million, marking a year-over-year increase of 3379.22%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
- According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Operating Income is -$11.3 million, which was up 5220.24% from -$18.4 million recorded in Q3 2025.
- In the past 5 years, Enanta Pharmaceuticals' Operating Income registered a high of -$11.3 million during Q4 2025, and its lowest value of -$39.5 million during Q1 2023.
- Its 5-year average for Operating Income is -$28.8 million, with a median of -$30.2 million in 2021.
- Per our database at Business Quant, Enanta Pharmaceuticals' Operating Income plummeted by 15010.53% in 2021 and then soared by 5220.24% in 2025.
- Quarter analysis of 5 years shows Enanta Pharmaceuticals' Operating Income stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then dropped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
- Its Operating Income was -$11.3 million in Q4 2025, compared to -$18.4 million in Q3 2025 and -$18.9 million in Q2 2025.